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ASTHMA IS AN IMPORTANT national
health priority because of its high and
increasing prevalence, high morbidity
and mortality, and direct and indirect
costs. Representative population sur-
veys of adult asthma have put the preva-
lence at 12% of the population1 with
significant impact on quality of life.2
Furthermore, the cost of asthma has
been equated with that of higher profile
conditions, such as cardiovascular dis-
ease,3,4 with much of this being attrib-
uted to the severe end of the asthma
spectrum.4,5 It is also at this end of the
spectrum that asthma has been associ-
ated with significant comorbidities,
especially depression.6-10
Apart from a randomly selected tele-
phone survey sample in California,6
most of the studies that have investi-
gated depression as a comorbidity of
asthma have been drawn from hospital7
or general practice populations,8 or
from specific subgroups such as patients
with chronic illnesses in the American
Medical Outcomes Study,8 or military
personnel.10 While these studies high-
light the problem, the generalisability of
their findings to the broader asthma
population is limited.
Evidence-based decisions about
asthma and depression that will inform
health policy and intervention are best
made from population samples that
identify prevalence rates of asthma,
describe problem subgroups and related
phenomena, and estimate the potential
for improved health outcomes.
In this study we aimed to assess
asthma, depression and quality of life in
a representative population sample.
More specifically, we aimed to investi-
gate the relationship between depres-
sion and known correlates of asthma
severity, including nocturnal symp-
toms,11,12 morning symptoms of
wheeze,12 number of hospital admis-
sions,13,14 use of preventer medica-
tion,15 and days lost from work.16 Such
information may guide not only clinical
management of asthma, but also public
health policy of this national health
priority area, thereby enhancing quality
of life for people with asthma.
METHODS
The data used in this study were
obtained from the 1998 South Austral-
ian Health Omnibus Survey. This is an
annual face-to-face population survey of
the South Australian population and
has operated each year at the same time
since 1990, with consistent survey
methods which have been described in
detail elsewhere.17 Data were weighted
to the nearest available (1996) Census
data to provide estimates that were
representative of the South Australian
population. Formal approval was
granted by the Health Omnibus Survey
Steering Committee of South Australia.
To determine doctor-diagnosed
asthma, participants were asked if they
had ever had asthma, whether a doctor
confirmed their asthma, and if they still
had asthma. If they answered yes to all
these questions, they were asked about
indicators of asthma severity:
■ How often do you waken during the
night with asthma?;
■ In the last 12 months have you had
any hospital admissions for asthma
where you stayed for at least one night?;
and
■ In the last 12 months have you had
any days lost from work, school or home
duties from asthma?
The dyspnoea dimension of the
Asthma Quality of Life Questionnaire18
was used to determine dyspnoea. Par-
ticipants were also asked if they used
preventer medication regularly, and
whether they wakened in the morning
with other symptoms. Demographic
questions were also asked (age, sex,
marital status, area of residence, coun-
try of birth, educational qualifications
and income).
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Depression was assessed by means of
the PRIME-MD questionnaire, which
has been validated to provide estimates
of mental disorder comparable with
those found using structured and longer
diagnostic interviews.19 In the analyses
of this study, the categories of major
depressive disorder, dysthymia, minor
depressive disorder and bipolar disorder
were collapsed to provide estimates of
major depression and all depression.
The Short-Form-36 (SF-36), a
health-related quality-of-life question-
naire was also included to assess the
quality of life associated with the differ-
ent asthma severity indicators. The SF-
36 has been validated for use in Aus-
tralia,20 and norms were calculated for
the South Australian population for
comparison with each of the asthma
severity indicators.  The SF-36 com-
prises 36 questions which measure
eight dimensions of health: physical
functioning, role limitations due to
physical health, bodily pain, general
health, vitality, social functioning, role
limitations due to emotional health,
and mental health. In addition, physi-
cal and mental component summary
scales can be derived.
Statistical analyses
Data were analysed using the Statistical
Package for the Social Sciences
(SPSS)21 and EpiInfo.22 The variables
of age, sex, depression, body mass
index, education, and migrant, work,
income and relationship status, were
included in a univariate analysis in
which odds ratios were calculated. Vari-
ables that were statistically significant at
the univariate stage were then included
in a logistic regression analysis. A series
of multiple analysis of variance
(MANOVA) analyses was conducted to
examine the relationship between each
asthma severity indicator and SF-36
dimension. The MUPLUS procedure
was used to produce weighted means
for each symptom variable, controlling
for age and sex.23 Mean SF-36 scores
were compared using t tests.
Standard scores were calculated for
both the physical and mental health
components summary scales of the
SF-36 by dividing the difference
between the quality-of-life scores for
each symptom severity indicator and the
norm of the South Australian popula-
tion by the standard deviation of the
South Australian population.24
RESULTS
From the 4400 households selected,
111 were found to be vacant dwellings.
From the remaining 4289 dwellings,
3010 interviews were conducted
(70.2% response rate). Non-response
was due to refusal (658), contact not
being established after six visits (408),
language barrier (73), the selected
respondent being absent for the dura-
tion of the survey (71) and illness (69).
The mean age of respondents was
43.9 years (95% CI, 43.2–44.5). There
were 1464 males (48.7%) and 1546
females (51.4%). The population point
prevalence of asthma in this study was
9.9% (299 of the 3010 participants;
95% CI, 8.8%–11.0%). Box 1 shows
the demographic variables that were sig-
nificantly associated with asthma after
logistic regression analysis were migrant
status, sex and all depression.
Box 2 shows that there were statisti-
cally significant increases in major
depression associated with dyspnoea,
wakening at night and morning symp-
toms for those with these asthma severity
indicators compared with those without
them. There was also a statistically sig-
nificantly higher rate of major depression
among those with asthma (14.4% [43/
299]) compared with those without
asthma (5.7% [154/2711]; P = 0.000).
This was also the case for all depression,
with a rate of 22.1% (66/299) among
those with asthma compared with
2: Prevalence of major or all types of depression for those with or without 
each asthma symptom
Prevalence
Asthma severity indicator Major depression (n=43) All depression (n=66)
Dyspnoea
Yes (n = 43) 32.6%* (14/43) 44.2%* (19/43)
No (n = 257) 11.3% (29/257) 17.9% (46/257)
Wakening at night
Yes (n = 38) 34.2%* (13/38 ) 47.4%* (18/38)
No (n = 261) 11.5% (30/261) 18.4% (48/261)
Preventer medication
Yes (n = 202) 16.3% (33/202) 22.8% (46/202)
No (n = 95) 10.5% (10/95) 18.9% (18/95)
Morning symptoms
Yes (n = 108) 25.0%* (27/108) 35.2%* (38/108)
No (n = 191) 8.4% (16/191) 14.1% (27/191)
Days lost from normal activities
Yes (n = 57) 19.3% (11/57) 28.1% (16/57)
No (n = 242) 13.2% (32/242) 20.7% (50/242)
Hospitalised in the last 12 months 
Yes (n = 15) 13.3% (2/15) 20.0% (3/15)
No (n = 285) 14.4% (41/285) 22.1% (63/285)
* Significantly higher than those without the symptoms at P < 0.001.
1: Predictors of asthma determined by logistic regression
Variable Odds ratio (95% CI) P
Female sex 1.55 (1.22–1.99) 0.003
Depression 1.40 (1.04–1.88) 0.026
Australian born 1.60 (1.18–2.18) 0.003
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16.7% (452/2711) among those without
asthma (P = 0.03). We did not compare
depression rates across the asthma
severity variables because they are not
independent groups.
Box 3 shows that dyspnoea, wakening
at night, and morning symptoms also
have greatest impact on reducing qual-
ity-of-life scores for all of the SF-36
dimensions (P < 0.01). Of interest is the
observation that hospital admissions are
associated with lower scores of three
physical health dimensions (physical
functioning, bodily pain and general
heal th) and  socia l  funct ioning
(P < 0.01). Wakening at night, days lost
from usual activities, morning symp-
toms and dyspnoea were also associated
with significantly lower quality-of-life
scores on the SF-36 mental and physi-
cal health components summaries.
Box 4 compares the SF-36 physical
and mental components summary for
the asthma severity indicators standard-
ised to South Australian population
norms. An effect size of 0.2 (or a fifth) of
a standard deviation is described as small
or mild; an effect size of 0.5 is described
as moderate; and an effect size of 0.8 or
greater as large.25 There was a large
effect on quality of life for wakening at
night and dyspnoea, a moderate effect
for days lost from normal activities, hos-
pital admission in the last 12 months and
morning symptoms, and a small effect
for use of preventer medications.
DISCUSSION
There is no doubt that asthma is signifi-
cantly associated with depressive disor-
ders. Furthermore, three specific
symptoms — dyspnoea, wakening at
night with asthma symptoms, and
morning symptoms — are particularly
strongly associated with depression.
There was also a significant and clini-
cally important impact on the quality of
life of those who reported wakening at
night, morning symptoms and dysp-
noea. This effect was at least doubled
for both the physical and mental health
quality-of-life dimensions when com-
pared with the other indicators of
asthma severity.
Our findings are consistent with those
of other studies,6-10 but go further by
specifically delineating the strong rela-
tionship between depression, asthma
severity indicators and quality of life in a
random and representative community
sample.
3: Short-Form-36 (SF-36) quality-of-life dimension and summary component scores (and 95% confidence 
intervals) for those with and without each asthma severity factor
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The comorbidity of asthma and
depression challenges clinicians to eval-
uate patients carefully, as wakening at
night, a diurnal mood variation with
symptoms that are worse in the morn-
ing, and dyspnoea as part of associated
anxiety and agitation can also be symp-
toms of depression.26
There are potential limitations to this
study. The presence of asthma was
detemined from patient self-report, as
was the presence of asthma severity
indicators, and no quantification of pul-
monary function was available. Simi-
larly, depression was detected on the
basis of responses to a standard check-
list of symptoms presented by a trained
health interviewer, rather than a clini-
cian. Nevertheless, our findings for the
prevalence of asthma and depression
were within the range of other epidemi-
ological studies.6,27
It is pertinent to consider how depres-
sion may affect asthma management. It
has been shown that, in problem solv-
ing, patients with depression were less
able to narrow down the possible range
of solutions to a problem and perse-
vered with unconfirmed solutions,28
and depression has been associated with
impaired decision making and poor per-
formance on more complex tasks.29
There are also documented effects of
depression on memory,30 attention31
and decision making. All of these cogni-
tive mechanisms are involved in patient
compliance with treatment, and are
therefore relevant in self-management
plans and expected management out-
comes.32 Serious deficiencies in making
decisions to seek medical help or call an
ambulance have been reported in cases
of a slow-onset asthma attack.33 This
report also noted serious discrepancies
in terms of patient knowledge of their
asthma; even patients who had a reason-
able idea of what to do in an asthma
attack were frequently unable to put
their knowledge into practice when nec-
essary, leading to life-threatening situa-
tions. It is possible that emotional
factors, including depression, may have
influenced such behaviour, and further
studies targeting this depression in
asthma are indicated. Indeed, our find-
ings support the conclusion of one
study of depressive symptoms and out-
come in asthma that, “these relatively
unexplored patient-centered variables
in asthma are potentially modifiable and
may offer new ways to intervene and
improve asthma outcomes”.7
Our results, from a random and rep-
resentative population sample, rather
than a clinical sample, show not only
the important comorbidity of depres-
sion with asthma, but also confirm the
previously acknowledged severity symp-
toms of asthma and their impact on
quality of life. However, those severity
symptoms are often associated with
depression, and therefore asthma guide-
lines need to consider depression in
diagnosis and management to improve
outcome. While it is correctly stated in
the National Asthma Campaign
Guidelines3,4 that caution should be
exercised in the use of sedatives, it is
noteworthy that no mention is made of
the potential value of antidepressant
measures, including medication, as
these data suggest that they may have an
important role to play.
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ASTHMA IS AN IMPORTANT national
health priority because of its high and
increasing prevalence, high morbidity
and mortality, and direct and indirect
costs. Representative population sur-
veys of adult asthma have put the preva-
lence at 12% of the population1 with
significant impact on quality of life.2
Furthermore, the cost of asthma has
been equated with that of higher profile
conditions, such as cardiovascular dis-
ease,3,4 with much of this being attrib-
uted to the severe end of the asthma
spectrum.4,5 It is also at this end of the
spectrum that asthma has been associ-
ated with significant comorbidities,
especially depression.6-10
Apart from a randomly selected tele-
phone survey sample in California,6
most of the studies that have investi-
gated depression as a comorbidity of
asthma have been drawn from hospital7
or general practice populations,8 or
from specific subgroups such as patients
with chronic illnesses in the American
Medical Outcomes Study,8 or military
personnel.10 While these studies high-
light the problem, the generalisability of
their findings to the broader asthma
population is limited.
Evidence-based decisions about
asthma and depression that will inform
health policy and intervention are best
made from population samples that
identify prevalence rates of asthma,
describe problem subgroups and related
phenomena, and estimate the potential
for improved health outcomes.
In this study we aimed to assess
asthma, depression and quality of life in
a representative population sample.
More specifically, we aimed to investi-
gate the relationship between depres-
sion and known correlates of asthma
severity, including nocturnal symp-
toms,11,12 morning symptoms of
wheeze,12 number of hospital admis-
sions,13,14 use of preventer medica-
tion,15 and days lost from work.16 Such
information may guide not only clinical
management of asthma, but also public
health policy of this national health
priority area, thereby enhancing quality
of life for people with asthma.
METHODS
The data used in this study were
obtained from the 1998 South Austral-
ian Health Omnibus Survey. This is an
annual face-to-face population survey of
the South Australian population and
has operated each year at the same time
since 1990, with consistent survey
methods which have been described in
detail elsewhere.17 Data were weighted
to the nearest available (1996) Census
data to provide estimates that were
representative of the South Australian
population. Formal approval was
granted by the Health Omnibus Survey
Steering Committee of South Australia.
To determine doctor-diagnosed
asthma, participants were asked if they
had ever had asthma, whether a doctor
confirmed their asthma, and if they still
had asthma. If they answered yes to all
these questions, they were asked about
indicators of asthma severity:
■ How often do you waken during the
night with asthma?;
■ In the last 12 months have you had
any hospital admissions for asthma
where you stayed for at least one night?;
and
■ In the last 12 months have you had
any days lost from work, school or home
duties from asthma?
The dyspnoea dimension of the
Asthma Quality of Life Questionnaire18
was used to determine dyspnoea. Par-
ticipants were also asked if they used
preventer medication regularly, and
whether they wakened in the morning
with other symptoms. Demographic
questions were also asked (age, sex,
marital status, area of residence, coun-
try of birth, educational qualifications
and income).
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Depression was assessed by means of
the PRIME-MD questionnaire, which
has been validated to provide estimates
of mental disorder comparable with
those found using structured and longer
diagnostic interviews.19 In the analyses
of this study, the categories of major
depressive disorder, dysthymia, minor
depressive disorder and bipolar disorder
were collapsed to provide estimates of
major depression and all depression.
The Short-Form-36 (SF-36), a
health-related quality-of-life question-
naire was also included to assess the
quality of life associated with the differ-
ent asthma severity indicators. The SF-
36 has been validated for use in Aus-
tralia,20 and norms were calculated for
the South Australian population for
comparison with each of the asthma
severity indicators.  The SF-36 com-
prises 36 questions which measure
eight dimensions of health: physical
functioning, role limitations due to
physical health, bodily pain, general
health, vitality, social functioning, role
limitations due to emotional health,
and mental health. In addition, physi-
cal and mental component summary
scales can be derived.
Statistical analyses
Data were analysed using the Statistical
Package for the Social Sciences
(SPSS)21 and EpiInfo.22 The variables
of age, sex, depression, body mass
index, education, and migrant, work,
income and relationship status, were
included in a univariate analysis in
which odds ratios were calculated. Vari-
ables that were statistically significant at
the univariate stage were then included
in a logistic regression analysis. A series
of multiple analysis of variance
(MANOVA) analyses was conducted to
examine the relationship between each
asthma severity indicator and SF-36
dimension. The MUPLUS procedure
was used to produce weighted means
for each symptom variable, controlling
for age and sex.23 Mean SF-36 scores
were compared using t tests.
Standard scores were calculated for
both the physical and mental health
components summary scales of the
SF-36 by dividing the difference
between the quality-of-life scores for
each symptom severity indicator and the
norm of the South Australian popula-
tion by the standard deviation of the
South Australian population.24
RESULTS
From the 4400 households selected,
111 were found to be vacant dwellings.
From the remaining 4289 dwellings,
3010 interviews were conducted
(70.2% response rate). Non-response
was due to refusal (658), contact not
being established after six visits (408),
language barrier (73), the selected
respondent being absent for the dura-
tion of the survey (71) and illness (69).
The mean age of respondents was
43.9 years (95% CI, 43.2–44.5). There
were 1464 males (48.7%) and 1546
females (51.4%). The population point
prevalence of asthma in this study was
9.9% (299 of the 3010 participants;
95% CI, 8.8%–11.0%). Box 1 shows
the demographic variables that were sig-
nificantly associated with asthma after
logistic regression analysis were migrant
status, sex and all depression.
Box 2 shows that there were statisti-
cally significant increases in major
depression associated with dyspnoea,
wakening at night and morning symp-
toms for those with these asthma severity
indicators compared with those without
them. There was also a statistically sig-
nificantly higher rate of major depression
among those with asthma (14.4% [43/
299]) compared with those without
asthma (5.7% [154/2711]; P = 0.000).
This was also the case for all depression,
with a rate of 22.1% (66/299) among
those with asthma compared with
2: Prevalence of major or all types of depression for those with or without 
each asthma symptom
Prevalence
Asthma severity indicator Major depression (n=43) All depression (n=66)
Dyspnoea
Yes (n = 43) 32.6%* (14/43) 44.2%* (19/43)
No (n = 257) 11.3% (29/257) 17.9% (46/257)
Wakening at night
Yes (n = 38) 34.2%* (13/38 ) 47.4%* (18/38)
No (n = 261) 11.5% (30/261) 18.4% (48/261)
Preventer medication
Yes (n = 202) 16.3% (33/202) 22.8% (46/202)
No (n = 95) 10.5% (10/95) 18.9% (18/95)
Morning symptoms
Yes (n = 108) 25.0%* (27/108) 35.2%* (38/108)
No (n = 191) 8.4% (16/191) 14.1% (27/191)
Days lost from normal activities
Yes (n = 57) 19.3% (11/57) 28.1% (16/57)
No (n = 242) 13.2% (32/242) 20.7% (50/242)
Hospitalised in the last 12 months 
Yes (n = 15) 13.3% (2/15) 20.0% (3/15)
No (n = 285) 14.4% (41/285) 22.1% (63/285)
* Significantly higher than those without the symptoms at P < 0.001.
1: Predictors of asthma determined by logistic regression
Variable Odds ratio (95% CI) P
Male sex 1.55 (1.22–1.99) 0.003
Depression 1.40 (1.04–1.88) 0.026
Overseas born 1.60 (1.18–2.18) 0.003
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16.7% (452/2711) among those without
asthma (P = 0.03). We did not compare
depression rates across the asthma
severity variables because they are not
independent groups.
Box 3 shows that dyspnoea, wakening
at night, and morning symptoms also
have greatest impact on reducing qual-
ity-of-life scores for all of the SF-36
dimensions (P < 0.01). Of interest is the
observation that hospital admissions are
associated with lower scores of three
physical health dimensions (physical
functioning, bodily pain and general
heal th) and  socia l  funct ioning
(P < 0.01). Wakening at night, days lost
from usual activities, morning symp-
toms and dyspnoea were also associated
with significantly lower quality-of-life
scores on the SF-36 mental and physi-
cal health components summaries.
Box 4 compares the SF-36 physical
and mental components summary for
the asthma severity indicators standard-
ised to South Australian population
norms. An effect size of 0.2 (or a fifth) of
a standard deviation is described as small
or mild; an effect size of 0.5 is described
as moderate; and an effect size of 0.8 or
greater as large.25 There was a large
effect on quality of life for wakening at
night and dyspnoea, a moderate effect
for days lost from normal activities, hos-
pital admission in the last 12 months and
morning symptoms, and a small effect
for use of preventer medications.
DISCUSSION
There is no doubt that asthma is signifi-
cantly associated with depressive disor-
ders. Furthermore, three specific
symptoms — dyspnoea, wakening at
night with asthma symptoms, and
morning symptoms — are particularly
strongly associated with depression.
There was also a significant and clini-
cally important impact on the quality of
life of those who reported wakening at
night, morning symptoms and dysp-
noea. This effect was at least doubled
for both the physical and mental health
quality-of-life dimensions when com-
pared with the other indicators of
asthma severity.
Our findings are consistent with those
of other studies,6-10 but go further by
specifically delineating the strong rela-
tionship between depression, asthma
severity indicators and quality of life in a
random and representative community
sample.
3: Short-Form-36 (SF-36) quality-of-life dimension and summary component scores (and 95% confidence 
intervals) for those with and without each asthma severity factor
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The comorbidity of asthma and
depression challenges clinicians to eval-
uate patients carefully, as wakening at
night, a diurnal mood variation with
symptoms that are worse in the morn-
ing, and dyspnoea as part of associated
anxiety and agitation can also be symp-
toms of depression.26
There are potential limitations to this
study. The presence of asthma was
detemined from patient self-report, as
was the presence of asthma severity
indicators, and no quantification of pul-
monary function was available. Simi-
larly, depression was detected on the
basis of responses to a standard check-
list of symptoms presented by a trained
health interviewer, rather than a clini-
cian. Nevertheless, our findings for the
prevalence of asthma and depression
were within the range of other epidemi-
ological studies.6,27
It is pertinent to consider how depres-
sion may affect asthma management. It
has been shown that, in problem solv-
ing, patients with depression were less
able to narrow down the possible range
of solutions to a problem and perse-
vered with unconfirmed solutions,28
and depression has been associated with
impaired decision making and poor per-
formance on more complex tasks.29
There are also documented effects of
depression on memory,30 attention31
and decision making. All of these cogni-
tive mechanisms are involved in patient
compliance with treatment, and are
therefore relevant in self-management
plans and expected management out-
comes.32 Serious deficiencies in making
decisions to seek medical help or call an
ambulance have been reported in cases
of a slow-onset asthma attack.33 This
report also noted serious discrepancies
in terms of patient knowledge of their
asthma; even patients who had a reason-
able idea of what to do in an asthma
attack were frequently unable to put
their knowledge into practice when nec-
essary, leading to life-threatening situa-
tions. It is possible that emotional
factors, including depression, may have
influenced such behaviour, and further
studies targeting this depression in
asthma are indicated. Indeed, our find-
ings support the conclusion of one
study of depressive symptoms and out-
come in asthma that, “these relatively
unexplored patient-centered variables
in asthma are potentially modifiable and
may offer new ways to intervene and
improve asthma outcomes”.7
Our results, from a random and rep-
resentative population sample, rather
than a clinical sample, show not only
the important comorbidity of depres-
sion with asthma, but also confirm the
previously acknowledged severity symp-
toms of asthma and their impact on
quality of life. However, those severity
symptoms are often associated with
depression, and therefore asthma guide-
lines need to consider depression in
diagnosis and management to improve
outcome. While it is correctly stated in
the National Asthma Campaign
Guidelines3,4 that caution should be
exercised in the use of sedatives, it is
noteworthy that no mention is made of
the potential value of antidepressant
measures, including medication, as
these data suggest that they may have an
important role to play.
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Correction
Re: “Does a combined program of
dietary modification and physical
activity or the use of metformin
reduce  the  conver s ion  f rom
impaired glucose tolerance to type 2
diabetes?”, the EBM: Trials on Trial
article by Dorothy E M Mackerras
in the 7 April issue of the Journal
(Med J Aust 2003; 178: 346-347), 
in which the title was incorrect. The
title should have been “Does dietary
modification and/or physical activity
reduce the progress ion f rom
impaired glucose tolerance to type 
2 diabetes?”. The article by Dr
Mackerras that also dealt with met-
formin was published in the 
17 February issue. ❏
The 5-minute herb and dietary supplement 
consult. Fugh-Berman A. Philadelphia: 
Lippincott Williams and Wilkins, 2003 
(xv + 475 pp $132) ISBN 0683302736.
Alcohol and the developing world: a public 
health perspective. Room R, Jernigan D, 
Carlini-Marlatt B, Gureje O, Makela K, 
Marshall M, Medina-Mora ME, Monteiro M, 
Parry C, Partanen J, Riley L, Saxena S. 
Helsinki: Finnish Foundation for Alcohol 
Studies and World Health Organization, 2002 
(276 pp $33.10) ISBN 951 9192 63 8.
Analytical neurology: examining the evidence 
for clinical practice. Benatar M. Amsterdam: 
Butterworth-Heinemann, 2003 (xvi + 328 pp 
$86.90) ISBN 0750674407.
Atlas of travel medicine and health. Chiodini 
JBL. Hamilton ONT: BC Decker, 2003 (vii 
+ 136 pp + CDROM $131.30) ISBN 
1550091891.
Bennett and Elliott’s Physiology and medicine 
of diving. Brubakk AO, Neuman TS (eds). 
Edinburgh: Saunders, 2003 (xii + 779 pp 
$319) ISBN 0702025712.
Eating disorders. How to have real control. 
Brigham S. Sydney: Australian Women’s 
Weekly health series, 2003 (96 pp $12.95) 
ISBN 1876624884.
Ethical choices in long-term care: what does 
justice require? Geneva: World Health 
Organization, 2002 (xii + 91 pp $22.75) ISBN 
9291562285.
Ethics and evidence-based medicine. 
Fallibility and responsibility in clinical science. 
Goodman KW. Cambridge: Cambridge 
University Press, 2003 (xii + 168 pp $69.95) 
ISBN 052176539.
Exotic viral diseases. A global guide. Berger 
SA, Calisher CH, Keystone JS. Hamilton ONT: 
BC Decker, 2003 (xii + 252 pp + CDROM 
$71.50) ISBN 1550092057.
Fatigue. Krupp LB. Philadelphia: Butterworth 
Heinemann, 2003 (ix + 246 pp $55) ISBN 
075067038X.
Headaches. Relief at last. Gressor M. Sydney: 
Australian Women’s Weekly health series, 
2003 (96 pp $12.95) ISBN 1876624922.
Helminth control in school-age children. A 
guide for managers of control programmes. 
Montresor A, Crompton DWT, Gyorkos TW, 
Saviolo L. Geneva: World Health 
Organization, 2002 (viii + 64 pp $33.85) 
ISBN 9241545569.
Insomnia. How to sleep easy. Lack L, Wright 
H, Bearpark H. Sydney: Australian Women’s 
Weekly health series, 2003 (96 pp $12.95) 
ISBN 1876624965.
Irritable bowel syndrome. Ellard K. Sydney: 
Australian Women’s Weekly health series, 
2003 (96 pp $12.95) ISBN 1876624973.
Journeys in healing. How others have 
triumphed over disease and disability. 
Matthews S. Sydney: Finch, 2003 (vi + 250 pp 
$24.95) ISBN 1876451424.
Mosby’s color atlas and text of diabetes and 
endocrinology. Belchetz P, Hammond PJ. 
Edinburgh: Mosby, 2003 (viii + 419 pp 
$115.50) ISBN 0723431043.
Practical chemotherapy. A multidisciplinary 
approach. Summerhayes M, Daniels S. 
Abingdon: Radcliffe Medical, 2003 (xv + 
398 pp $104.75) ISBN 1857759656.
Practical general practice. Guidelines for 
effective clinical management. Khot A, 
Polmear A (eds). London: Butterworth-
Heinemann, 2003 (xvii + 509 pp + CDROM 
$145.20) ISBN 0750649119.
Providing global public goods. Managing 
globalization. Kaul I, Conceicao P, Le Goulven 
K, Mendoza RU (eds). New York: Oxford 
University Press, 2003 (xxii + 646 pp $58.20) 
ISBN 0195157419.
Success in Africa: the Onchocerciasis 
Control Programme in West Africa, 
1974-2002. Geneva: World Health 
Organization, 2002 (vii + 72 pp $33.90) 
ISBN 9241562277.
Summary measures of population health. 
Concepts, ethics, measurement and 
applications. Murray CJL, Salomon JA, 
Mathers CD, Lopez AD (eds). Geneva: World 
Health Organization, 2002 (xxviii + 770 pp 
$75) ISBN 92415455181.
Tropical health in the Top End. An introduction 
for health practitioners. Darwin: Top End 
Division of General Practice, 2003 (164 pp 
$42.50) ISBN 1877021024.
Urology secrets. Resnick MI, Novick AC. 
Philadelphia: Hanley and Belfus, 2003 
(xv + 341 pp $99.09) ISBN 1560535105.
Vaccines and biologicals. WHO vaccine-
preventable diseases: monitoring system, 
2002 global summary. Geneva: World Health 
Organization, 2002 (vii + 380 pp + CDROM 
electronic copy available from http://
www.who.int/vaccines-documents/DoxGen/
H3DoxNew.htm) ISBN none.
Vital essence. Understanding the lymphatic 
system in health and disease. Lymphoedema. 
Piller N. Adelaide: Flinders University, 2002 
(1 CD ROM $88) ISBN none.
Whiplash and other useful illnesses. Malleson 
A. Montreal: McGill-Queen’s University Press, 
2002 (viii + 527 pp $62.95) ISBN 
0773523332.
WHO manual of diagnostic imaging. 
Radiographic anatomy and interpretation 
of the musculoskeletal system. Ostensen H, 
Pettersson H (eds). Geneva: World Health 
Organization, 2002 (vi + 203 pp $95.20) 
ISBN 9241545550.
WHO monographs on selected medicinal 
plants. Vol 2. Geneva: World Health 
Organization, 2002 (v + 355 pp $146.35) 
ISBN 9241545372.
books received
